Are Anthem Biosciences Ltd latest results good or bad?

Anthem Biosciences Ltd reported its Q4 FY26 results, showcasing significant operational achievements. The company recorded a net profit of ₹189.76 crores, reflecting a notable increase compared to the previous quarter, where it was ₹92.82 crores. This performance indicates a strong recovery from the subdued results of the prior quarter. Revenue for the same quarter reached ₹610.94 crores, marking a substantial rise from ₹423.15 crores in Q3 FY26. This quarter also saw the highest sales in the company's history, with a sequential growth of 44.38% and a year-on-year growth of 26.44%. The operating margin improved to 43.74%, up from 37.15% in the previous quarter, indicating enhanced operational efficiency. Additionally, the return on equity (ROE) stood at 24.12%, reflecting strong capital efficiency. The company’s performance was bolstered by effective cost management and a favorable project mix, leading to a PAT margin of 31.06%, which is the highest in seven quarters. Despite these strong operational results, Anthem Biosciences trades at a high valuation relative to industry averages, which has led to an adjustment in its evaluation. The company’s financial metrics, including a P/E ratio of 72 times trailing earnings and a price-to-book ratio of 15.30 times, suggest that the market has priced in substantial growth expectations. Overall, Anthem Biosciences demonstrated a remarkable turnaround in Q4 FY26, characterized by robust revenue growth and improved profitability metrics, while also facing challenges related to its elevated valuation in the market.